Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanreqing capsules for acute exacerbation of mild to moderate chronic obstructive pulmonary disease
CTR20213412Phase 2Active
- Sponsor
- Shanghai Kaibao Pharmaceutical
- Start
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tanreqing capsules with Placebo (2 arms). Primary endpoint: BCSS score change from baseline. Started Jan 2022; status: active.
02
Drugs
Tanreqing Capsules
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20213412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213412.